Gilead Sciences, Inc. (GILD)
Health Care · Biotechnology · US stock · S&P 500 component
$156.19
▼ -1.18 (0.75%)
Fair valueFair
$228 +45.7% to fair value
$114fair band $137–$319$341
Day's range
$155.62 – $157.58
52-week range
$111.27 – $160.51
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that researches, develops and commercialises medicines. Its products are mainly known for treating HIV, and it also offers treatments for hepatitis, liver disease, cancer and other serious conditions, including cell therapy through its Kite unit. Its customers are wholesalers, pharmacies and healthcare providers who supply patients, along with government health programmes in many countries.
Gilead earns revenue from prescription medicines, with a large portion coming from antiviral drugs. Over the last twelve months revenue was $30.5 billion, growing at 2.6% a year across the last three years. The operating margin is -8.2%, which means the business recorded an operating loss, and the return on the capital invested in it is -6%. The company pays a dividend with a yield of 2.1%. On the site's X-Ray Score it receives 44 out of 100.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $111.27 – $160.51Volume 7,770,900Daily, split-adjusted
Vitals
Market cap$194.1B
52-week range$111.27 – $160.51
Volume (last day)7,770,900
P/E (TTM)–
EBIT / EV yield-1.2%
Free-cash-flow yield6.7%
Dividend yield2.1%
Revenue (TTM)$30.5B
Net income (TTM)−$3.2B
Operating margin-8.2%
Return on capital-5.7%
Debt incl. leases$26.2B
Cash & securities$3.2B
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$228
Fair
+45.7% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is High, so the safety margin is 40%.
Loss-making or insufficient history: no DCF/EPV
Price $156
Undervalued < $137Fair $137 – $319Overvalued > $319
Peer multiples
$228
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Weak business, fairly priced
The price sits inside our fair-value band. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Fair
55/100
Priced about in line with its sector.
See the numbers →
EBIT / EV yield-1.2%
Free-cash-flow yield6.7%
Fair value vs price1.5×
Growth
Weak
45/100
Growing slower than most of its sector.
See the numbers →
Revenue growth (3y)2.6%
EPS growth (3y)23.0%
Growth consistency90%
Profitability
Weak
38/100
Earns lower returns on its capital than most peers.
See the numbers →
Return on invested capital-5.7%
Operating margin-8.2%
Gross profitability49.1%
Financial health
Weak
38/100
Balance sheet is more stretched than most peers.
See the numbers →
Piotroski F-Score8 / 9
Interest cover-2.5×
Dividends
Weak
49/100
Dividend is modest or less certain than peers.
See the numbers →
Dividend yield2.1%
Dividends vs free cash flow31%
Dividend growth2.6%
Quarterly results: last 6 quarters
-0.3%
Mar '25
+1.8%
Jun '25
+3.0%
Sep '25
+4.7%
Dec '25
+4.4%
Mar '26
+10.2%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $7.8B, diluted EPS $-8.45.
Compare with peers
INCY Incyte Corp81 VRTX Vertex Pharmaceuticals...55 AMGN Amgen Inc51 REGN Regeneron Pharmaceutic...50Other Biotechnology companies by X-Ray Score.
Fundamentals checklist
● 6 Good · ● 2 Average · ● 7 BadCash quality
Earnings backed by cashGood
Free-cash-flow yieldGood
Risk models
Altman Z''Bad
Piotroski F-ScoreGood
Growth
EPS growth (3y)Good
Free-cash-flow growth (3y)Average
Revenue growth (3y)Bad
Growth consistencyAverage
Balance sheet
Current ratioBad
Interest coverBad
Valuation
Fair value vs priceGood
EBIT / EV yieldBad
Profitability
Return on invested capitalBad
Operating marginBad
Gross profitabilityGood
Each check is graded against the company's sector, not a fixed number. Checklist score 45/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $27.3B | $27.3B | $27.1B | $28.8B | $29.4B |
| Operating income | $9.9B | $7.3B | $7.6B | $1.7B | $10.0B |
| Net income | $6.2B | $4.6B | $5.7B | $480M | $8.5B |
| Operating cash flow | $11.4B | $9.1B | $8.0B | $10.8B | $10.0B |
| Operating margin | 36.3% | 26.9% | 28.0% | 5.8% | 34.0% |
| Free cash flow | $10.8B | $8.3B | $7.4B | $10.3B | $9.5B |
| Diluted EPS | $4.93 | $3.64 | $4.50 | $0.38 | $6.78 |
Fiscal years, from SEC filings.
Technical summary
Daily
Strongly bullish
12 bullish · 3 neutral · 1 bearish
Weekly
Strongly bullish
11 bullish · 1 neutral · 0 bearish
Monthly
Strongly bullish
7 bullish · 0 neutral · 1 bearish
Moving averages (daily)
| SMA 10 | 149.9 | Bullish |
| EMA 10 | 151.7 | Bullish |
| SMA 20 | 150.0 | Bullish |
| EMA 20 | 150.0 | Bullish |
| SMA 50 | 146.4 | Bullish |
| EMA 50 | 145.9 | Bullish |
| SMA 100 | 137.6 | Bullish |
| EMA 100 | 141.2 | Bullish |
| SMA 200 | 136.7 | Bullish |
| EMA 200 | 135.0 | Bullish |
Oscillators (daily)
| RSI (14) | 63.64 | Neutral |
| MACD (12, 26) | 2.06 | Bullish |
| Momentum (12) | 4.79 | Bullish |
| Stochastic %K (14) | 75.88 | Neutral |
| Williams %R (14) | -24.12 | Neutral |
| CCI (20) | 174.6 | Bearish |
Pivot points (classic, last session)
S3 153.4 | S2 154.5 | S1 155.3 | Pivot 156.5 | R1 157.3 | R2 158.4 | R3 159.3 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
3.25 USD
Yield on today's price
2.08%
Frequency
Quarterly
Next ex-dividend date
Not announced
| Ex-dividend date | Amount per share |
|---|---|
| 15 Sep 2026 | 0.8200 |
| 15 Jun 2026 | 0.8200 |
| 13 Mar 2026 | 0.8200 |
| 15 Dec 2025 | 0.7900 |
| 15 Sep 2025 | 0.7900 |
| 13 Jun 2025 | 0.7900 |
| 14 Mar 2025 | 0.7900 |
| 13 Dec 2024 | 0.7700 |
| 13 Sep 2024 | 0.7700 |
| 14 Jun 2024 | 0.7700 |
| 14 Mar 2024 | 0.7700 |
| 14 Dec 2023 | 0.7500 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
GILD SEC filings
6 Aug 2026
10-QSEC EDGAR
Quarterly report
4 Aug 2026
8-KSEC EDGAR
Results of operations
20 May 2026
8-KSEC EDGAR
Entered a material agreement; Other events
18 May 2026
424B5SEC EDGAR
424B5
14 May 2026
424B5SEC EDGAR
424B5
7 May 2026
10-QSEC EDGAR
Quarterly report
7 May 2026
8-KSEC EDGAR
Results of operations
4 May 2026
8-KSEC EDGAR
Shareholder vote results
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.